Rock Springs Capital Management LP Corvus Pharmaceuticals, Inc. Transaction History

Rock Springs Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$1.74 - $5.98 $261,000 - $897,000	-150,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$2.56 - $5.44 $640,000 - $1.36 Million	-250,000 Reduced 62.5%	150,000 $816,000
Q4 2018 Feb 14, 2019	SELL	$3.29 - $8.94 $575,750 - $1.56 Million	-175,000 Reduced 30.43%	400,000 $1.47 Million
Q1 2018 May 15, 2018	BUY	$7.48 - $11.53 $1.14 Million - $1.76 Million	152,400 Added 36.06%	575,000 $6.63 Million
Q3 2017 Nov 14, 2017	BUY	$11.3 - $17.23 $4.78 Million - $7.28 Million	422,600	422,600 $6.74 Million

103

37.5M

868K

338K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $163M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.